Eloxx Pharmaceuticals, Inc.: directors' dealings · United States · SEC (Form 4)

About Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc. is a U.S.-listed biopharmaceutical company traded on the NASDAQ in the United States. The company focuses on developing next-generation therapies for rare and ultra-rare genetic diseases, using small-molecule approaches designed to promote readthrough of premature stop codons (“nonsense” mutations) and restore production of full-length functional proteins. In practical terms, Eloxx operates in precision medicine and rare-disease biotech, where valuation is driven less by current revenue and more by clinical validation, intellectual property, and financing capacity. Eloxx traces its roots to Eloxx Pharmaceuticals, Ltd., with scientific and corporate links to Israel, while its U.S. operating footprint is centered in Massachusetts. Public company information shows a headquarters/contact presence in Watertown, Massachusetts, and SEC filing materials list a mailing/business address in Arlington, Massachusetts. That geographic setup reflects a transatlantic structure: U.S.-based public-company administration and financing, combined with research and IP elements associated with Israel and external academic collaborators. The company’s leadership has been stable in recent years, with Sumit Aggarwal serving as President and Chief Executive Officer since April 2021. Its board also includes experienced biotech, venture capital, and healthcare executives. The company’s core asset is ELX-02, its lead investigational product candidate. Eloxx positions ELX-02 as a small-molecule drug designed to restore production of full-length proteins in diseases caused by nonsense mutations. The company currently highlights Alport syndrome as a lead program, while also working on other rare-disease opportunities and IND-enabling studies in areas such as kidney and ocular genetic disorders. Eloxx also references platform technologies including TURBO-ZM™ and eukaryotic ribosomal selective glycosides (ERSGs), which are intended to underpin a broader pipeline beyond a single indication. From a competitive standpoint, Eloxx remains an early-stage clinical biotech rather than a commercial pharmaceutical company. It competes in a crowded field that includes rare-disease drug developers, gene-therapy companies, and other platform-driven players pursuing mutation-correction or readthrough strategies. The company’s strategic challenge is to translate promising biology into reproducible human data and then secure the capital needed to advance development. Recent public activity has included ongoing SEC filings, including Form 4 insider transactions filed in May 2026, underscoring that the market is still tracking corporate and ownership changes closely. For investors in France, Belgium, and Switzerland, Eloxx should be viewed as a high-risk, high-upside Nasdaq biotech story with meaningful binary clinical catalysts and a long development runway.